Time filter

Source Type

Pan Y.,Capital Medical University | Wang A.,Capital Medical University | Liu G.,Capital Medical University | Zhao X.,Capital Medical University | And 122 more authors.
Journal of the American Heart Association | Year: 2014

Background: Treatment with the combination of clopidogrel and aspirin taken soon after a transient ischemic attack (TIA) or minor stroke was shown to reduce the 90-day risk of stroke in a large trial in China, but the cost-effectiveness is unknown. This study sought to estimate the cost-effectiveness of the clopidogrel-aspirin regimen for acute TIA or minor stroke. Methods and Results: A Markov model was created to determine the cost-effectiveness of treatment of acute TIA or minor stroke patients with clopidogrel-aspirin compared with aspirin alone. Inputs for the model were obtained from clinical trial data, claims databases, and the published literature. The main outcome measure was cost per quality-adjusted life-years (QALYs) gained. Oneway and multivariable probabilistic sensitivity analyses were performed to test the robustness of the findings. Compared with aspirin alone, clopidogrel-aspirin resulted in a lifetime gain of 0.037 QALYs at an additional cost of CNY 1250 (US$ 192), yielding an incremental cost-effectiveness ratio of CNY 33 800 (US$ 5200) per QALY gained. Probabilistic sensitivity analysis showed that clopidogrel-aspirin therapy was more cost-effective in 95.7% of the simulations at a willingness-to-pay threshold recommended by the World Health Organization of CNY 105 000 (US$ 16 200) per QALY. Conclusions: Early 90-day clopidogrel-aspirin regimen for acute TIA or minor stroke is highly cost-effective in China. Although clopidogrel is generic, Plavix is brand in China. If Plavix were generic, treatment with clopidogrel-aspirin would have been cost saving. © 2014 The Authors. Source

Liu Y.,Shanxi Medical University | Wu Z.,Fenyang Hospital Of Shanxi Province | Guo J.,Fenyang Hospital Of Shanxi Province | Ren Z.,Fenyang Hospital Of Shanxi Province | And 2 more authors.
Zhonghua Shiyan Yanke Zazhi/Chinese Journal of Experimental Ophthalmology | Year: 2016

Background: The study on eye surface damage following phacoemulsification with intraocular lens (IOL) implantation is increasingly concerned,and these symptoms were associated with dry eye and often treated by polyethylene glycol eyedrops to remit the discomfortableness. Recombinant bovine basic fibroblast growth factor (rb-bFGF) eyedrops contains neurotrophic factors, but its effect on eye surface damage is worth researching. Objective: This study was to evaluate the repair effects of rb-bFGF on ocular surface injury after phacoemulsification with IOL implantation. Methods: A randomized controlled trail was designed. Ninety eyes of 72 consecutive patients with age-related cataract were enrolled in Fenyang Hospital of Shanxi Province from September 2010 to August 2013 under the informed consent. Phacoemulsification with IOL implantation was performed on all the eyes, and tobramycin and dexamethasone eye drops was used for 15 days as basis therapy. According to the treatment sequence,the operative eyes were assigned to rb-bFGF eyedrops group, polyethylene glycol eyedrops group and basis therapy group. rb-bFGF drops and polyethylene glycol drops were topically administered 4 times per day since the first day after surgery for consecutive 30 days in corresponding group, and only basis therapy was maintained in the basis therapy grouply. Corneal fluorescence (FL) staining scores, breakup time of tear film (BUT) and Schirmer I test (SIt) without topical anesthesia were examined in 1 day before operation and 1 day, 7 days, 15 days and 30 days after operation. The efficacy was intergrouply compared. Results: No significant differences were seen in the demography and the relevant surface examinational outcomes among the rb-bFGF group, polyethylene glycol drops group and the basis therapy group before surgery (age: F=1.50; gender; χ2=0.336, both at >0.05; FL: F=0.31; BUT: F=0.65; SIt; F=0.57; all at P>0.05). Compared with the before operation, FL scores were obviously increased, and BUT values were reduced and SIt values were elavated in all the eyes early stage of surgey and then gradually improved with the lapse of postoperative time, showing significant differences (Ftime=7.83, 7.32, 7.17, all at P<0.01). The FL scores, BUT and SIt in 15 days after surgery in the rb-bFGF drops group and 30 days after surgery in the polyethylene glycol drops group was closed to those of before surgery (all at P>0.05). However,there were still significant differences between the before and after operation in the basis were closed to those of before surgery therapy group (all at P<0.05). In addition, significant differences were found in corneal FL scores, BUT and SIt among these three groups (Pgroup=5.08, 4.15, 4.61, all at P<0.05). In postoperative 15 days and 30 days, the S I t values were (12.32±1.18) and (11.32±1.98) mm/5 min,which were significantly lower than (14.36±1.77) and (13.36±2.32) mm/5 min in the polyethylene glycol drops group and (17.25±2.24) and (13.25±2.53) mm/5 min in the basis therapy group (all at P<0.05). Conclusions: The topical application of rb-bFGF combined with tobramycin and dexamethasone eyedrops can improve the dry eye-related symptoms and promote the repair of the ocular surface injury after phacoemulsification with IOL implantation, and the clinical efficacy of rb-bFGF eyedrops is better than that of polyethylene glycol eyedrops or only tobramycin and dexamethasone eyedrops. Copyright © 2016 by the Chinese Medical Association. Source

Zhang P.,Fenyang Hospital Of Shanxi Province | Chen Y.,Fenyang Hospital Of Shanxi Province | Gang C.,Fenyang Hospital Of Shanxi Province | Ma B.,Fenyang Hospital Of Shanxi Province | He P.,Fenyang Hospital Of Shanxi Province
Cancer Research and Clinic | Year: 2014

Objective: To investigate the role of Ki-67, c-myc, p53 in human in esophageal cancer. Methods: 25 specimens of human esophageal cancer as observe group and 25 adjacent normal specimens as control group were selected. Expressions of Ki-67, c-myc, p53 protein were detected by immunohistochemical staining. Results: Protein expressions levels of Ki-67, c-myc and p53 in human esophageal cancer were significantly higher than those in control group 5.0, 2.0, 3.0 vs 1.0, 0.5, 0.3, respectively (all P < 0.05). The expression level of Ki-67 protein in high differentiation group were significantly lower than that of moderate and low differentiation group (3.0 vs 6.0, P < 0.05). In human esophageal cancer specimens, the expression level of Ki-67 protein was positively correlated with that of c-myc (P < 0.05). Conclusion: The expressions of Ki-67, c-myc and p53 are higher in esophageal cancer, which are increased with the higher differentiation. Ki-67, c-myc and p53 proteins may be taken as potential markers in human esophageal cancer. Source

Discover hidden collaborations